Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World check: ovarian cancer drug niraparib under the microscope

NCT ID NCT04295577

Knowledge-focused Sponsor: Royal Marsden NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked back at 388 women with advanced ovarian, fallopian tube, or peritoneal cancer who were taking the drug niraparib as maintenance therapy. Researchers wanted to see how often serious side effects happened and how patients used the drug in real-life UK clinics. No new treatment was given; it simply observed what happened during routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

388 people

The number who actually took part.

Started

Feb 2020

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with advanced ovarian fallopian tube and primary peritoneal cancer, who are/have/ will be receiving Niraparib as maintenance treatment

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patient 18 years old or over * Patients who are planned to receive Niraparib for advanced ovarian fallopian tube or primary peritoneal cancer, * Patients who have previously commenced maintenance Niraparib prior to study opening at site * Deceased patients who have previously been prescribed Niraparib * Patients able to give written informed consent, complete questionnaires in English and comply with study procedures (if applicable). Exclusion Criteria: * Patients aged \<18 years old * Patients unable to give informed consent, complete questionnaires in English or comply with study procedures (if applicable).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fallopian tube cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube neoplasm ovarian cancer peritoneum cancer primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fallopian tube cancer Ovarian cancer Peritoneal cancer

Contacts and locations

Locations

  • Addenbrookes Hospital

    Cambridge, CB2 0QQ, United Kingdom

  • Barts Health NHS Trust

    London, E1 1FR, United Kingdom

  • Belfast Health & Social Care Trust

    Belfast, BT9 7AB, United Kingdom

  • Morecambe Bay NHS Trust

    Lancaster, United Kingdom

  • Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust

    Northwood, HA6 2RN, United Kingdom

  • Northampton General Hospital NHS Trust

    Northampton, NN1 5BD, United Kingdom

  • Queen's Hospital

    Romford, RM7 0AG, United Kingdom

  • Royal Cornwall Hospitals NHS Trust

    Truro, TR1 3LJ, United Kingdom

  • Royal Marsden NHS Foundation Trust

    Sutton, SM2 5PT, United Kingdom

  • Royal United Hospitals Bath

    Bath, BA1 3NG, United Kingdom

  • St James's University Hospital

    Leeds, LS9 7TF, United Kingdom

  • University Hospital Southampton NHS Foundation Trust

    Southampton, SO16 5YA, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, B15 2TH, United Kingdom

  • University Hospitals Bristol NHS Foundation Trust

    Bristol, BS2 8ED, United Kingdom

  • Velindre Cancer Centre, Velindre University NHS Trust

    Cardiff, CF14 2TL, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.